NUVL

Nuvalent, Inc. [NUVL] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

NUVL Stock Summary

Top 10 Correlated ETFs

NUVL


Top 10 Correlated Stocks

NUVL


In the News

06:30 29 Sep 2023 NUVL

Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium

Company plans to host a conference call on October 13, 2023 CAMBRIDGE, Mass. , Sept. 18, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced it will present preliminary dose-escalation data from its ongoing ALKOVE-1 Phase 1/2 clinical trial of NVL-655 at the 35th AACR-NCI-EORTC (ANE) Symposium taking place October 11-15, 2023, in Boston, Massachusetts.

06:30 29 Sep 2023 NUVL

Nuvalent to Participate in Upcoming September Investor Conferences

CAMBRIDGE, Mass. , Aug. 31, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.

10:03 29 Sep 2023 NUVL

Deerfield Management Company, L.P.

Deerfield Management Company, L.P. (Series C), a renowned investment firm, recently made a significant addition to its portfolio.

06:30 29 Sep 2023 NUVL

Nuvalent to Participate in Upcoming August Investor Conferences

CAMBRIDGE, Mass. , Aug. 1, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.

09:57 29 Sep 2023 NUVL

Recent Price Trend in Nuvalent, Inc. (NUVL) is Your Friend, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Nuvalent, Inc. (NUVL) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

10:03 29 Sep 2023 NUVL

Nuvalent, Inc. (NUVL) Is a Great Choice for 'Trend' Investors, Here's Why

Nuvalent, Inc. (NUVL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

06:30 29 Sep 2023 NUVL

Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023)

CAMBRIDGE, Mass. , March 23, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced an upcoming poster presentation for the ongoing Phase 1/2 ALKOVE-1 study of its ALK-selective inhibitor, NVL-655.

05:59 29 Sep 2023 NUVL

Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023

CAMBRIDGE, Mass. , March 14, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced an upcoming preclinical data poster presentation supporting the ongoing clinical development of its ALK-selective inhibitor, NVL-655.

06:30 29 Sep 2023 NUVL

Nuvalent to Present at the 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. , Jan. 4, 2023 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.

10:12 29 Sep 2023 NUVL

MDA Breakout Stocks Week 1 - January 2023: High-Frequency Gainers To Give You An Edge

Two new Breakout Stocks for Week 1 with better than 10% short-term upside potential and two Dow 30 Picks. Average cumulative returns for 2022 reached +142.69% YTD. The streak of weekly picks gaining over 10% in less than a week of trading days has reached 235 out of 293 trading weeks (80.4%) not counting multiple gainers.

NUVL Financial details

Company Rating
Buy
Market Cap
2.49B
Income
-88.08M
Revenue
0
Book val./share
7.41
Cash/share
7.58
Dividend
-
Dividend %
-
Employees
78
Optionable
No
Shortable
Yes
Earnings
09 Nov 2023
P/E
-29.46
Forward P/E
-
PEG
12.55
P/S
-
P/B
6.16
P/C
6.06
P/FCF
-31.54
Quick Ratio
20.74
Current Ratio
21.01
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.63
EPS next Y
-
EPS next Q
-
EPS this Y
-30.52%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
41.67%
-
-
-
-
SMA20
-
SMA50
2.33%
SMA100
18.92%
Inst Own
97.47%
Inst Trans
1.01%
ROA
-20%
ROE
-23%
ROC
-0.27%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
57.02M
Shs Float
22.86M
-
-
-
-
Target Price
-
52W Range
15.565-50.585
52W High
-8.1%
52W Low
+206.33%
RSI
55
Rel Volume
0.6
Avg Volume
351.61K
Volume
210.91K
Perf Week
7.81%
Perf Month
11.77%
Perf Quarter
78.52%
Perf Half Y
63.7%
-
-
-
-
Beta
1.35276
-
-
Volatility
1.5%, 2.26%
Prev Close
0.7%
Price
45.95
Change
4.79%

NUVL Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
0000
Net income per share
-0.73-0.64-2.13-1.48
Operating cash flow per share
-0.6-0.65-1.84-1.31
Free cash flow per share
-0.6-0.65-1.84-1.31
Cash per share
0.190.4513.239.51
Book value per share
-1.07-1.3713.089.32
Tangible book value per share
-1.07-1.3713.089.32
Share holders equity per share
-1.07-1.3713.089.32
Interest debt per share
0.130.100.09
Market cap
303.22M428.7M414.76M1.48B
Enterprise value
302.37M420.6M346.24M1.24B
P/E ratio
-25.68-29.45-8.95-20.17
Price to sales ratio
0000
POCF ratio
-31.46-28.68-10.37-22.77
PFCF ratio
-31.46-28.68-10.37-22.77
P/B Ratio
-17.57-13.691.463.19
PTB ratio
-17.57-13.691.463.19
EV to sales
0000
Enterprise value over EBITDA
-29.19-24.88-7.56-14.37
EV to operating cash flow
-31.37-28.14-8.66-19.04
EV to free cash flow
-31.37-28.14-8.66-19.04
Earnings yield
-0.04-0.03-0.11-0.05
Free cash flow yield
-0.03-0.03-0.1-0.04
Debt to equity
-0.13-0.0700
Debt to assets
0.660.2100
Net debt to EBITDA
0.080.481.52.81
Current ratio
0.762.4333.0724.54
Interest coverage
000-20.24
Income quality
0.821.030.860.79
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
0000
Research and developement to revenue
0000
Intangibles to total assets
0000
Capex to operating cash flow
0000
Capex to revenue
0000
Capex to depreciation
0000
Stock based compensation to revenue
0000
Graham number
4.194.4325.0317.6
ROIC
0.690.58-0.16-0.17
Return on tangible assets
-3.56-1.37-0.16-0.15
Graham Net
-1.09-1.3812.829.11
Working capital
-1.04M6.27M281.84M458.51M
Tangible asset value
-17.26M-31.32M285.04M462.98M
Net current asset value
-17.26M-31.32M281.84M458.51M
Invested capital
-0.13-0.0700
Average receivables
0000
Average payables
0987.5K2.07M5.04M
Average inventory
0000
Days sales outstanding
0000
Days payables outstanding
0000
Days of inventory on hand
0000
Receivables turnover
0000
Payables turnover
0000
Inventory turnover
0000
ROE
0.680.46-0.16-0.16
Capex per share
0000

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
Revenue per share
00000
Net income per share
-0.38-0.39-0.37-0.36-0.51
Operating cash flow per share
-0.32-0.38-0.33-0.43-0.39
Free cash flow per share
-0.32-0.38-0.33-0.43-0.39
Cash per share
5.324.968.817.947.58
Book value per share
5.244.898.647.837.41
Tangible book value per share
5.244.898.647.837.41
Share holders equity per share
5.244.898.647.837.41
Interest debt per share
-0.01-0.010.06-0.090.09
Market cap
655.21M941.1M1.6B1.48B2.4B
Enterprise value
579.29M864.79M1.35B1.39B2.33B
P/E ratio
-9-12.35-20.19-18.33-20.61
Price to sales ratio
00000
POCF ratio
-42.34-51.78-89.81-60.6-108.34
PFCF ratio
-42.34-51.78-89.81-60.6-108.34
P/B Ratio
2.593.983.453.335.69
PTB ratio
2.593.983.453.335.69
EV to sales
00000
Enterprise value over EBITDA
-30.92-42.42-46.24-45.99-68.32
EV to operating cash flow
-37.43-47.58-76.21-56.91-105.14
EV to free cash flow
-37.43-47.58-76.21-56.91-105.14
Earnings yield
-0.03-0.02-0.01-0.01-0.01
Free cash flow yield
-0.02-0.02-0.01-0.02-0.01
Debt to equity
00000
Debt to assets
00000
Net debt to EBITDA
4.053.748.252.982.08
Current ratio
25.7918.924.5426.8121.01
Interest coverage
70.1630.34-9.236.02-6.85
Income quality
0.840.920.680.970.76
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
6.666.588.467.929.23
ROIC
-0.07-0.08-0.05-0.05-0.08
Return on tangible assets
-0.07-0.08-0.04-0.04-0.07
Graham Net
5.114.698.447.647.22
Working capital
248.79M232.27M458.51M439.27M416.2M
Tangible asset value
252.99M236.58M462.98M443.97M421.15M
Net current asset value
248.79M232.27M458.51M439.27M416.2M
Invested capital
00000
Average receivables
00000
Average payables
4.14M4.32M5.91M6.81M7.28M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.07-0.08-0.04-0.05-0.07
Capex per share
00000

NUVL Frequently Asked Questions

What is Nuvalent, Inc. stock symbol ?

Nuvalent, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol NUVL

What is Nuvalent, Inc. stock quote today ?

Nuvalent, Inc. stock price is $45.95 today.

Is Nuvalent, Inc. stock public?

Yes, Nuvalent, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap